» Articles » PMID: 35582674

Osteosarcopenia in Autoimmune Cholestatic Liver Diseases: Causes, Management, and Challenges

Overview
Specialty Gastroenterology
Date 2022 May 18
PMID 35582674
Authors
Affiliations
Soon will be listed here.
Abstract

Primary biliary cholangitis and primary sclerosing cholangitis (PSC) are the most common cholestatic liver diseases (CLD) in adults and are both characterized by an immune pathogenesis. While primary biliary cholangitis is a model autoimmune disease, with over 90% of patients presenting very specific autoantibodies against mitochondrial antigens, PSC is considered an immune mediated disease. Osteoporosis is the most common bone disease in CLD, resulting in frequent fractures and leading to significant morbidity. Further, sarcopenia is emerging as a frequent complication of chronic liver diseases with a significant prognostic impact and severe implications on the quality of life of patients. The mechanisms underlying osteoporosis and sarcopenia in CLD are still largely unknown and the association between these clinical conditions remains to be dissected. Although timely diagnosis, prevention, and management of osteosarcopenia are crucial to limit the consequences, there are no specific guidelines for management of osteoporosis and sarcopenia in patients with CLD. International guidelines recommend screening for bone disease at the time of diagnosis of CLD. However, the optimal monitoring strategies and treatments have not been defined yet and vary among centers. We herein aim to comprehensively outline the pathogenic mechanisms and clinical implications of osteosarcopenia in CLD, and to summarize expert recommendations for appropriate diagnostic and therapeutic approaches.

Citing Articles

Multi-modal molecular determinants of clinically relevant osteoporosis subtypes.

Yuan C, Yu X, Wang J, Shu B, Wang X, Huang C Cell Discov. 2024; 10(1):28.

PMID: 38472169 PMC: 10933295. DOI: 10.1038/s41421-024-00652-5.


Prevalence and risk factors of osteoporosis detected by dual-energy X-ray absorptiometry among Chinese patients with primary biliary cholangitis.

Chen J, Liu Y, Bi Y, Wang X World J Gastroenterol. 2023; 29(29):4580-4592.

PMID: 37621753 PMC: 10445004. DOI: 10.3748/wjg.v29.i29.4580.

References
1.
Szalay F, Folhoffer A, Horvath A, Csak T, Speer G, Nagy Z . Serum leptin, soluble leptin receptor, free leptin index and bone mineral density in patients with primary biliary cirrhosis. Eur J Gastroenterol Hepatol. 2005; 17(9):923-8. DOI: 10.1097/00042737-200509000-00007. View

2.
Raszeja-Wyszomirska J, Miazgowski T . Osteoporosis in primary biliary cirrhosis of the liver. Prz Gastroenterol. 2014; 9(2):82-7. PMC: 4108749. DOI: 10.5114/pg.2014.42502. View

3.
Jackson R, Mysiw W . Insights into the epidemiology of postmenopausal osteoporosis: the Women's Health Initiative. Semin Reprod Med. 2014; 32(6):454-62. DOI: 10.1055/s-0034-1384629. View

4.
Pares A, Guanabens N . Primary biliary cholangitis and bone disease. Best Pract Res Clin Gastroenterol. 2018; 34-35:63-70. DOI: 10.1016/j.bpg.2018.06.005. View

5.
Lanza E, Masetti C, Messana G, Muglia R, Pugliese N, Ceriani R . Sarcopenia as a predictor of survival in patients undergoing bland transarterial embolization for unresectable hepatocellular carcinoma. PLoS One. 2020; 15(6):e0232371. PMC: 7299358. DOI: 10.1371/journal.pone.0232371. View